Mcintyrewilkerson4590

034, with smell/taste dysfunction to have the most increment. The latter symptom recovered completely in 81% and dysgeusia developed in 9.5% at three months, and it recovered completely in all patients at six months.

Although COVID-19 may produce severe lower airways disease, it has modest effect on nose and paranasal sinuses. Moreover, smell/taste dysfunction is a prominent symptom, but it usually recovers dramatically.

Although COVID-19 may produce severe lower airways disease, it has modest effect on nose and paranasal sinuses. Moreover, smell/taste dysfunction is a prominent symptom, but it usually recovers dramatically.

Assess the feasibility of using light from artificial sun lamps to decontaminate N95 filtering facepiece respirators (FFRs) contaminated with SARS-CoV-2.

FFR coupons or whole FFRs contaminated with 5 log

TCID

(target concentration) SARS-CoV-2 in culture media, simulated saliva, or simulated lung fluid were dried for 1-2h, then exposed to light from tanning and horticulture lamps to assess decontamination. Exposed coupons and whole FFRs showed SARS-CoV-2 inactivation for all matrices tested. Furthermore, FFRs still met performance specifications after five decontamination cycles.

It is feasible that artificial sunlight from these sun lamps can be used to decontaminate FFRs provided the UV dose is sufficient and the light is unobstructed. Furthermore, decontamination can be performed up to five times without degrading FFR performance.

This research shows a proof of principle that artificial sun lamps may be an option to decontaminate SARS-CoV-2 on N95 FFRs. TH5427 supplier UV doses required for inactivation to levels below detection ranged from 4 to 37·8Jcm

depending on the light source, virus matrix and FFR type.

This research shows a proof of principle that artificial sun lamps may be an option to decontaminate SARS-CoV-2 on N95 FFRs. UV doses required for inactivation to levels below detection ranged from 4 to 37·8 J cm-2 depending on the light source, virus matrix and FFR type.As one typical clean-energy technologies, lithium-metal batteries, especially high-energy-density batteries which use concentrated electrolytes hold promising prospect for the development of a sustainable world. However, concentrated electrolytes with aggregative configurations were achieved at the expense of using extra dose of costly and environmental-unfriendly salts/additives, which casts a shadow over the development of a sustainable world. Herein, without using any expensive salts/additives, we employed commercially-available low-cost and environmental-friendly molecular sieves (zeolite) to sieve the solvation sheath of lithium ions of classic commercialized electrolyte (LiPF6 -EC/DMC), and resulting in a unique zeolite sieved electrolyte which was more aggregative than conventional concentrated electrolytes. Inspiringly, the new-designed electrolyte exhibited largely enhanced anti-oxidation stability under high-voltage (4.6 volts) and elevated temperature (55 °C). NCM-811//Li cells assembled with this electrolyte delivered ultra-stable rechargeabilities (over 1000 cycles for half-cell; 300 cycles for pouch-cell). More importantly, sustainable NCM-811//Li pouch-cell with negligible capacity decay can also be obtained through using recyclable zeolite sieved electrolyte. This conceptually-new way in preparing safe and highly-efficient electrolyte by using low-price molecular sieve would accelerate the development of high-energy-density lithium-ion/lithium-metal batteries.

This study aimed to describe the real-world therapeutic management of patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) (LUTS/BPH) attending primary care and urology clinics in Spain.

This observational, retrospective, multicentre study included men ≥50years of age diagnosed with LUTS/BPH (≤8years prior to study visit) (N=670). Therapeutic management according to healthcare service (primary care vs. urology clinics) or progression criteria, proportion of patients with treatment change, patient profile according to therapy and evolution of LUTS severity were assessed.

Overall differences were noticed in the management of patients between healthcare service (P<.001) and with or without progression criteria (P<.05). Most patients received pharmacological treatment at diagnosis (70.7%; 474/670), which increased at study visit (81.6%; 547/670) with overall similar profiles between primary care and urology clinics for each therapy. α1-Blockers were the most usedboth primary care and urologists existing clinical guideline recommendations for the appropriate medical management of patients with LUTS/BPH.

Novel coronavirus disease 2019 (COVID-19) poses a huge threat to the global public health. This study aimed to identify predictive indicators of severe COVID-19.

We retrospectively collected clinical data on hospital admission of all patients with severe COVID-19 and a control cohort (11) of gender- and hospital-matched patients with mild disease from 13 designated hospitals in the Hebei Province between 22 January and 15 April 2020.

A total of 104 patients (52 with severe COVID-19 and 52 with mild disease) were included. Only age, fever, duration from symptom onset to confirmation, respiratory rate, percutaneous oxygen saturation (SpO

) and neutrophilic percentage were independent predictors of severe COVID-19. Age and neutrophilic percentage performed best in predicting severe COVID-19, followed by SpO

. 'Age+neutrophilic percentage' (the sum of age and neutrophilic percentage) (area under the curve [AUC] 0.900, 95% confidence interval [CI] 0.825-0.950, P<.001) and 'age and neutrophilic percentage' (the prediction probability of age and neutrophilic percentage for severe type obtained by logistic regression analysis) (AUC 0.899, 95% CI 0.824-0.949, P<.001) had excellent predictive performance for severe type. The optimal cut-off for 'age+neutrophilic percentage' was >119.1 (sensitivity, 86.5%; specificity, 84.6%; Youden index, 0.712).

The combination of age and neutrophil percentage could effectively predict severe COVID-19. The sum of age and neutrophil percentage was recommended for clinical application because of its excellent predictive value and practicability.

China Clinical Trial Registry, number ChiCTR2000030226. Registered 26 February 2020-Retrospectively registered, http//www.chictr.org.cn/showproj.aspx?proj=49855.

China Clinical Trial Registry, number ChiCTR2000030226. Registered 26 February 2020-Retrospectively registered, http//www.chictr.org.cn/showproj.aspx?proj=49855.